معرفی
Philip Debruyne is an Honorary Clinical Professor of Cancer Pharmacology at the University of Plymouth's School of Nursing and Midwifery, with additional honorary appointments at Anglia Ruskin University. As a Consultant Medical Oncologist and Clinical Pharmacologist at the Kortrijk Cancer Centre in Belgium, he specializes in gynaecologic and urologic cancers, early clinical trials, and geriatric oncology. His research integrates clinical pharmacology with cancer care innovations for vulnerable populations.
Dr. Debruyne holds an MD from Ghent University, a PhD in Medical Sciences, and an MSc in Pharmacology from Thomas Jefferson University. His research bridges geriatric oncology, clinical pharmacology, and quality-of-life studies in cancer survivors, developing novel therapeutic approaches for urogenital cancers and improving care models for older adults.
His published work demonstrates a focus on immunotherapy efficacy, geriatric assessment tools, and cancer survivorship. Recent articles explore pseudoprogression in renal cell carcinoma, fall prevention in frail oncology patients, and psychosocial care models. Research employs multicenter designs and data linkage methodologies to address health-care disparities in vulnerable populations.
Honors include the Pfizer Oncology Award (2020), Merck Sharp & Dohme International Fellowship, and grants from organizations including the King Baudouin Foundation. He leads collaborative initiatives within the European Organisation for Research and Treatment of Cancer and supervises clinical fellows in translational oncology research.
Dr. Debruyne directs clinical trials at the Kortrijk Cancer Centre and coordinates international research consortia focused on quality-of-life assessment tools and geriatric oncology interventions, integrating pharmacological and clinical expertise across European institutions.
